In the following study, we have explored the therapeutic potential of three active-site mTOR inhibitors, PP-242, OSI-027 and AZD-8055 against both T-ALL cell lines and primary samples from T-ALL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results